Muscle-on-Chip Repair Platforms: Revolutionizing Skeletal Muscle Regeneration and Disease Modeling

Abstract

Muscle-on-chip repair platforms represent an innovative intersection of tissue engineering, microfluidics, and regenerative medicine, enabling dynamic and physiologically relevant models for studying muscle physiology, pathology, and therapeutic repair. This review explores the scientific foundation, clinical applications, and recent advances in muscle-on-chip technologies, emphasizing their transformative potential in disease modeling, drug screening, and regenerative strategies for skeletal muscle injuries. With an emphasis on evidence-based findings and guideline-driven insights, the article addresses the mechanistic underpinnings, diagnostic integration, and translational relevance of these platforms for the modern healthcare landscape.

Introduction

Skeletal muscle injuries and degenerative myopathies present substantial clinical challenges, often resulting in impaired mobility, chronic disability, and significant healthcare costs. Traditional in vitro and in vivo models for muscle repair have limitations in recapitulating the complex microenvironment of human muscle tissue. Recent advances in organ-on-chip technology, specifically muscle-on-chip repair platforms, offer unprecedented opportunities to model human muscle physiology, investigate pathophysiological mechanisms, and evaluate regenerative therapies in a controlled, reproducible manner. This review aims to provide clinicians and researchers with a comprehensive overview of the design, application, and clinical relevance of muscle-on-chip platforms in the context of muscle repair and regeneration.

Epidemiology / Disease Burden

Musculoskeletal disorders, including traumatic muscle injuries, muscular dystrophies, and age-related sarcopenia, collectively affect hundreds of millions worldwide. According to recent epidemiological studies, the global prevalence of skeletal muscle disorders is rising, fueled by an aging population, increased participation in high-intensity sports, and higher survival rates among patients with chronic systemic diseases. The burden is reflected in reduced quality of life, loss of independence, and increased healthcare utilization. Traditional treatment approaches often fall short in restoring full muscle function, highlighting the urgent need for advanced platforms to study disease mechanisms and develop effective interventions.

Pathophysiology

Muscle tissue exhibits remarkable regenerative capacity, primarily mediated by satellite cells, but this process is compromised in conditions such as severe trauma, chronic inflammation, fibrosis, and genetic myopathies. Central to muscle repair is the orchestration of myogenic differentiation, extracellular matrix remodeling, vascular integration, and neuromuscular junction reformation. Muscle-on-chip platforms replicate key aspects of the muscle microenvironment, including biomechanical cues, perfusion, and cell-cell interactions, enabling mechanistic studies of regeneration and pathological processes like fibrosis and fatty infiltration. These platforms allow real-time analysis of contractility, metabolic function, and response to therapeutic agents under physiologically relevant conditions, bridging critical gaps left by static 2D cultures and animal models.

Risk Factors

Several patient-specific and environmental risk factors influence muscle injury and impaired regeneration. These include advanced age, genetic predispositions (e.g., mutations in dystrophin or sarcoglycan genes), comorbidities like diabetes or peripheral vascular disease, chronic corticosteroid use, and inadequate rehabilitation following injury. External factors such as repetitive strain, acute trauma, and exposure to myotoxic agents further compound risk. Muscle-on-chip models are uniquely suited to dissect the interplay of these risk factors by enabling controlled manipulation of genetic, biochemical, and mechanical variables, thus offering personalized insights into disease susceptibility and progression.

Clinical Features

Clinical manifestations of muscle injury and degeneration range from acute pain, swelling, and functional impairment to chronic weakness, atrophy, and contractures in progressive myopathies. Biomarker profiles, imaging findings (e.g., MRI, ultrasound), and functional assays (e.g., isometric strength testing) are integral to assessment but often lack predictive power for therapeutic response. Muscle-on-chip platforms facilitate the identification of dynamic biomarkers and functional readouts, such as force generation and calcium flux, that correlate with clinical outcomes. This enables the development of more precise diagnostic and prognostic tools for guiding patient management.

Diagnosis

Diagnosis of muscle disorders relies on a combination of clinical evaluation, laboratory testing (e.g., CK, LDH), electrophysiological studies, and tissue biopsy. However, these approaches are invasive, lack sensitivity for early changes, and often fail to capture the intricacies of human muscle pathophysiology. Muscle-on-chip platforms offer non-invasive, high-throughput alternatives for assessing muscle health, enabling real-time monitoring of tissue viability, contractility, and response to pharmacological interventions. Integration of patient-derived cells further enhances the relevance of these models for personalized diagnostics, particularly in rare or heterogeneous myopathies.

Treatment & Management

Current therapeutic strategies for muscle repair include conservative management (rest, physiotherapy), pharmacological agents (NSAIDs, corticosteroids), biologics (growth factors, anti-fibrotics), cell-based therapies (satellite cells, mesenchymal stem cells), and surgical interventions for severe injuries. Despite advances, outcomes remain suboptimal, with persistent deficits in muscle strength and structure. Muscle-on-chip platforms are actively used to screen and optimize therapeutic regimens, providing a controlled environment to evaluate efficacy, safety, and mechanism of action of candidate treatments before clinical translation. This accelerates the identification of novel agents and combinatorial strategies with superior regenerative potential.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advancements in muscle-on-chip technology, including the incorporation of 3D bioprinting, vascularized constructs, and multi-tissue integration for improved physiological relevance. Emerging therapies evaluated on these platforms include gene editing (CRISPR/Cas9-mediated correction of dystrophic mutations), biomaterial scaffolds loaded with growth factors, and engineered cell therapies with enhanced regenerative capacity. Advanced readout systems, such as real-time impedance monitoring and optogenetic stimulation, enable high-content analysis of muscle function and adaptation. These innovations have already yielded promising preclinical results and are poised to transform the pipeline for muscle repair therapeutics.

Guideline Recommendations

International guidelines, including those from the International Society for Cellular Therapy and the European Society for Muscle Research, increasingly advocate for the adoption of advanced in vitro models, such as muscle-on-chip platforms, for preclinical validation of regenerative therapies. These guidelines emphasize the need for robust, reproducible, and human-relevant data prior to clinical trials, as well as the integration of patient-derived cells for personalized research. Regulatory agencies are also developing frameworks for the qualification of organ-on-chip models as surrogates for animal testing, further accelerating their adoption in translational research and drug development.

Conclusion

Muscle-on-chip repair platforms have emerged as transformative tools for unraveling the complexities of muscle regeneration, enabling high-fidelity disease modeling, therapeutic screening, and personalized medicine approaches. Their capacity to mimic the human muscle microenvironment, provide dynamic functional readouts, and facilitate mechanistic studies positions them at the forefront of regenerative medicine innovation. Continued interdisciplinary collaboration, technological refinement, and adherence to evolving clinical guidelines will be essential to fully realize their potential in improving outcomes for patients with muscle injuries and degenerative disorders.